Nov 23 (Reuters) - Cyclopharm Ltd CYC.AX
* Received special protocol assessment (spa ) agreement1 from United States Food And Drug Administration
* Received special protocol assessment agreement1 for patient trials of its technegas product, to be known as cyc009
* Approval process remains on track for completion by mid2018 at a cost of less than $7 million usd Source text for Eikon: ID:nASX2Gqpsx Further company coverage: CYC.AX